Detailed Narrative
Q1 FY26 Financial Performance Overview
Akums Drugs reported a total income of ₹1,051 crores in Q1 FY26, reflecting a 2.4% year-on-year growth. The company's reported EBITDA stood at ₹156 crores, an increase of 19% YoY and 40% QoQ, with margins expanding by 208 basis points to 14.8%. Adjusted EBITDA, excluding other income, was ₹129 crores, growing 4% YoY, with adjusted margins at 12.6%. Adjusted PAT increased 13% YoY to ₹65 crores, demonstrating resilience despite industry headwinds🌐 like tepid volume growth below 0.40% and a 10-12% decline in API prices.
R&D and Product Pipeline Achievements
R&D remains a cornerstone of Akums' strategy, evidenced by achieving a cumulative milestone of 1,000 DCGI approvals in Q1 FY26. The company secured 27 DCGI approvals during the quarter, a significant improvement compared to the 31 approvals received for the entire previous year. Akums also obtained one patent for a niche formulation of Doxylamine and Pyridoxine and filed 24 new patents in its CDMO business. The commercialization of triple-layered tablets this quarter further highlights its focus on innovative dosage forms.
Global CDMO Expansion and European Market Entry
Akums is actively expanding its global CDMO footprint, having received its first European Dossier approval for Rivaroxaban, a drug with a global market exceeding USD 15 billion. The company also filed its first dossier in Switzerland for Dapagliflozin plus combination. ANVISA Brazil approval was secured for injectable plant 3, and GMP Russia approval for hormone plant 4. The European GMP audit for the plant is expected this quarter, with commercial supplies slated to begin from April 2027. A significant €100 million was received as part consideration for the European contract, bolstering the company's cash surplus to ₹1,518 crores.
Segmental Performance and Strategic Focus
The CDMO segment, a key growth driver, reported revenues of ₹813 crores, growing 4% YoY, with a healthy EBITDA margin of 14.7%. Domestic branded formulations grew 3.4% YoY to ₹107 crores, with an expected annual EBITDA margin of 18%. International branded formulations saw a 2.4% YoY growth to ₹35 crores, maintaining 23% EBITDA margins. Conversely, the API business experienced a 35% YoY revenue decline to ₹45 crores, resulting in a negative EBITDA of ₹6 crores, while the trade generic segment also posted a negative EBITDA of ₹5 crores as the company rationalizes underperforming units.
Capacity Expansion and New Product Launches
Akums is actively ramping up CAPEX on newer facilities, including its Penem and second dedicated injectable facilities. The Baddi facility is on track to commence commercial supplies of liquid products in H2 FY26, including oncology products, with a steroidal block planned for Q1 FY27. The Jammu plant is targeted to be operational by March 2027, with CAPEX continuing through the end of this year and the next 12-13 months. These expansions are crucial for supporting future growth and diversifying the product portfolio.
Outlook and Inorganic Growth Strategy
For the full year FY26, Akums targets mid-single-digit growth for its CDMO business, with EBITDA margins expected to remain in the 14-15% range. The domestic branded formulation segment is projected to maintain an 18% EBITDA margin. The company aims for a ₹20 crore EBITDA improvement in the API business this year. With a strong cash surplus of ₹1,518 crores, Akums is actively exploring inorganic growth opportunities, focusing on acquiring new dosage form capabilities or gaining access to new markets, both domestically and internationally.